305794-89-2

Upstream product

• 305794-43-8 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1'-(tert-butoxycarbonyl)-4'-methyl-1,4'-bipiperidine 
• 203187-77-3 1-{4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl}-2,2,2-trifluoroethanone 
• 305794-58-5 4'-methyl-4-(4-methylsulfanyl-benzoyl)-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 

Downstream Products

• 305794-32-5 C₂₄H₃₈N₂O₅S 
• 305794-62-1 (4-methanesulfonyl-phenyl)-(4'-methyl-[1,4']bipiperidinyl-4-yl)-methanone O-methyl-oxime 
• 305794-61-0 4-[(4-methanesulfonyl-phenyl)-methoxyimino-methyl]-4'-methyl-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3 -pyridinyl)carbonyl]-4′-methyl-1,4′-bipipefidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infec